scispace - formally typeset
Search or ask a question

Showing papers by "Federal University of São Paulo published in 2019"


Journal ArticleDOI
TL;DR: This is the first study to report global prevalence of obstructive sleep apnoea; with almost 1 billion people affected, and with prevalence exceeding 50% in some countries, effective diagnostic and treatment strategies are needed to minimise the negative health impacts and to maximise cost-effectiveness.

1,487 citations


Journal ArticleDOI
Oliver A. Cornely, Ana Alastruey-Izquierdo1, Dorothee Arenz2, Sharon C.-A. Chen3, Eric Dannaoui4, Bruno Hochhegger5, Bruno Hochhegger6, Martin Hoenigl7, Martin Hoenigl8, Henrik Jeldtoft Jensen9, Katrien Lagrou10, Russell E. Lewis11, Sibylle C. Mellinghoff2, Mervyn Mer12, Zoi D. Pana13, Danila Seidel2, Donald C. Sheppard14, Roger Wahba2, Murat Akova15, Alexandre Alanio16, Abdullah M. S. Al-Hatmi17, Sevtap Arikan-Akdagli15, Hamid Badali18, Ronen Ben-Ami19, Alexandro Bonifaz20, Stéphane Bretagne16, Elio Castagnola21, Methee Chayakulkeeree22, Arnaldo Lopes Colombo23, Dora E. Corzo-Leon24, Lubos Drgona25, Andreas H. Groll26, Jesús Guinea27, Jesús Guinea28, Claus Peter Heussel29, Ashraf S. Ibrahim30, Souha S. Kanj31, Nikolay Klimko, Michaela Lackner32, Frédéric Lamoth33, Fanny Lanternier4, Cornelia Lass-Floerl32, Dong-Gun Lee34, Thomas Lehrnbecher35, Badre E. Lmimouni, Mihai Mares, Georg Maschmeyer, Jacques F. Meis, Joseph Meletiadis36, Joseph Meletiadis37, C. Orla Morrissey38, Marcio Nucci39, Rita O. Oladele, Livio Pagano40, Alessandro C. Pasqualotto41, Atul Patel, Zdenek Racil, Malcolm Richardson, Emmanuel Roilides13, Markus Ruhnke, Seyedmojtaba Seyedmousavi42, Seyedmojtaba Seyedmousavi18, Neeraj Sidharthan43, Nina Singh44, Janos Sinko, Anna Skiada36, Monica A. Slavin45, Monica A. Slavin46, Rajeev Soman47, Brad Spellberg48, William J. Steinbach49, Ban Hock Tan50, Andrew J. Ullmann, Joerg J. Vehreschild35, Maria J G T Vehreschild35, Thomas J. Walsh51, P. Lewis White52, Nathan P. Wiederhold53, Theoklis E. Zaoutis54, Arunaloke Chakrabarti55 
Carlos III Health Institute1, University of Cologne2, University of Sydney3, Paris Descartes University4, Pontifícia Universidade Católica do Rio Grande do Sul5, Universidade Federal de Ciências da Saúde de Porto Alegre6, University of California, San Diego7, Medical University of Graz8, University of Copenhagen9, Katholieke Universiteit Leuven10, University of Bologna11, University of the Witwatersrand12, RMIT University13, McGill University14, Hacettepe University15, University of Paris16, Utrecht University17, Mazandaran University of Medical Sciences18, Tel Aviv University19, Hospital General de México20, Istituto Giannina Gaslini21, Mahidol University22, Federal University of São Paulo23, King's College, Aberdeen24, Comenius University in Bratislava25, Boston Children's Hospital26, Hospital General Universitario Gregorio Marañón27, Complutense University of Madrid28, University Hospital Heidelberg29, University of California, Los Angeles30, American University of Beirut31, Innsbruck Medical University32, University of Lausanne33, Catholic University of Korea34, Goethe University Frankfurt35, National and Kapodistrian University of Athens36, Erasmus University Rotterdam37, Monash University38, Federal University of Rio de Janeiro39, Catholic University of the Sacred Heart40, University of Health Sciences Antigua41, National Institutes of Health42, Amrita Institute of Medical Sciences and Research Centre43, University of Pittsburgh44, University of Melbourne45, Peter MacCallum Cancer Centre46, P. D. Hinduja Hospital and Medical Research Centre47, University of Southern California48, Duke University49, Singapore General Hospital50, NewYork–Presbyterian Hospital51, Cardiff University52, University of Texas Health Science Center at San Antonio53, Children's Hospital of Philadelphia54, Post Graduate Institute of Medical Education and Research55
TL;DR: Management of mucormycosis depends on recognising disease patterns and on early diagnosis, and limited availability of contemporary treatments burdens patients in low and middle income settings.
Abstract: Mucormycosis is a difficult to diagnose rare disease with high morbidity and mortality. Diagnosis is often delayed, and disease tends to progress rapidly. Urgent surgical and medical intervention is lifesaving. Guidance on the complex multidisciplinary management has potential to improve prognosis, but approaches differ between health-care settings. From January, 2018, authors from 33 countries in all United Nations regions analysed the published evidence on mucormycosis management and provided consensus recommendations addressing differences between the regions of the world as part of the "One World One Guideline" initiative of the European Confederation of Medical Mycology (ECMM). Diagnostic management does not differ greatly between world regions. Upon suspicion of mucormycosis appropriate imaging is strongly recommended to document extent of disease and is followed by strongly recommended surgical intervention. First-line treatment with high-dose liposomal amphotericin B is strongly recommended, while intravenous isavuconazole and intravenous or delayed release tablet posaconazole are recommended with moderate strength. Both triazoles are strongly recommended salvage treatments. Amphotericin B deoxycholate is recommended against, because of substantial toxicity, but may be the only option in resource limited settings. Management of mucormycosis depends on recognising disease patterns and on early diagnosis. Limited availability of contemporary treatments burdens patients in low and middle income settings. Areas of uncertainty were identified and future research directions specified.

842 citations


Journal ArticleDOI
TL;DR: There is a need for continued ongoing and future basic and clinical studies to better define whether vitamin D status can be optimized to improve many aspects of human health, and what is plausible regarding the health effects of vitamin D.
Abstract: The etiology of endemic rickets was discovered a century ago. Vitamin D is the precursor of 25-hydroxyvitamin D and other metabolites, including 1,25(OH)2D, the ligand for the vitamin D receptor (VDR). The effects of the vitamin D endocrine system on bone and its growth plate are primarily indirect and mediated by its effect on intestinal calcium transport and serum calcium and phosphate homeostasis. Rickets and osteomalacia can be prevented by daily supplements of 400 IU of vitamin D. Vitamin D deficiency (serum 25-hydroxyvitamin D <50 nmol/L) accelerates bone turnover, bone loss, and osteoporotic fractures. These risks can be reduced by 800 IU of vitamin D together with an appropriate calcium intake, given to institutionalized or vitamin D-deficient elderly subjects. VDR and vitamin D metabolic enzymes are widely expressed. Numerous genetic, molecular, cellular, and animal studies strongly suggest that vitamin D signaling has many extraskeletal effects. These include regulation of cell proliferation, immune and muscle function, skin differentiation, and reproduction, as well as vascular and metabolic properties. From observational studies in human subjects, poor vitamin D status is associated with nearly all diseases predicted by these extraskeletal actions. Results of randomized controlled trials and Mendelian randomization studies are supportive of vitamin D supplementation in reducing the incidence of some diseases, but, globally, conclusions are mixed. These findings point to a need for continued ongoing and future basic and clinical studies to better define whether vitamin D status can be optimized to improve many aspects of human health. Vitamin D deficiency enhances the risk of osteoporotic fractures and is associated with many diseases. We review what is established and what is plausible regarding the health effects of vitamin D.

543 citations


Journal ArticleDOI
TL;DR: Major changes to the structure of the I CD‐11 classification of mental disorders as compared to the ICD‐10 are described, and the development of two new ICD-11 chapters relevant to mental health practice are described.

416 citations


Posted ContentDOI
26 Jan 2019-bioRxiv
TL;DR: A meta-analysis of genome-wide studies of anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, and Tourette syndrome revealed a meaningful structure within the eight disorders identifying three groups of inter-related disorders.
Abstract: Genetic influences on psychiatric disorders transcend diagnostic boundaries, suggesting substantial pleiotropy of contributing loci. However, the nature and mechanisms of these pleiotropic effects remain unclear. We performed a meta-analysis of 232,964 cases and 494,162 controls from genome-wide studies of anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, and Tourette syndrome. Genetic correlation analyses revealed a meaningful structure within the eight disorders identifying three groups of inter-related disorders. We detected 109 loci associated with at least two psychiatric disorders, including 23 loci with pleiotropic effects on four or more disorders and 11 loci with antagonistic effects on multiple disorders. The pleiotropic loci are located within genes that show heightened expression in the brain throughout the lifespan, beginning in the second trimester prenatally, and play prominent roles in a suite of neurodevelopmental processes. These findings have important implications for psychiatric nosology, drug development, and risk prediction.

346 citations


Journal ArticleDOI
TL;DR: The RSNA Pediatric Bone Age Machine Learning Challenge showed how a coordinated approach to solving a medical imaging problem can be successfully conducted and will catalyze collaboration and development of ML tools and methods that can potentially improve diagnostic accuracy and patient care.
Abstract: Purpose The Radiological Society of North America (RSNA) Pediatric Bone Age Machine Learning Challenge was created to show an application of machine learning (ML) and artificial intelligence (AI) in medical imaging, promote collaboration to catalyze AI model creation, and identify innovators in medical imaging. Materials and Methods The goal of this challenge was to solicit individuals and teams to create an algorithm or model using ML techniques that would accurately determine skeletal age in a curated data set of pediatric hand radiographs. The primary evaluation measure was the mean absolute distance (MAD) in months, which was calculated as the mean of the absolute values of the difference between the model estimates and those of the reference standard, bone age. Results A data set consisting of 14 236 hand radiographs (12 611 training set, 1425 validation set, 200 test set) was made available to registered challenge participants. A total of 260 individuals or teams registered on the Challenge website. A total of 105 submissions were uploaded from 48 unique users during the training, validation, and test phases. Almost all methods used deep neural network techniques based on one or more convolutional neural networks (CNNs). The best five results based on MAD were 4.2, 4.4, 4.4, 4.5, and 4.5 months, respectively. Conclusion The RSNA Pediatric Bone Age Machine Learning Challenge showed how a coordinated approach to solving a medical imaging problem can be successfully conducted. Future ML challenges will catalyze collaboration and development of ML tools and methods that can potentially improve diagnostic accuracy and patient care. © RSNA, 2018 Online supplemental material is available for this article. See also the editorial by Siegel in this issue.

277 citations


Journal ArticleDOI
TL;DR: The FAIR Data Principles as discussed by the authors are a set of data reuse principles that focus on enhancing the ability of machines to automatically find and use the data, in addition to supporting its reuse by individuals.
Abstract: There is an urgent need to improve the infrastructure supporting the reuse of scholarly data. A diverse set of stakeholders-representing academia, industry, funding agencies, and scholarly publishers-have come together to design and jointly endorse a concise and measureable set of principles that we refer to as the FAIR Data Principles. The intent is that these may act as a guideline for those wishing to enhance the reusability of their data holdings. Distinct from peer initiatives that focus on the human scholar, the FAIR Principles put specific emphasis on enhancing the ability of machines to automatically find and use the data, in addition to supporting its reuse by individuals. This Comment is the first formal publication of the FAIR Principles, and includes the rationale behind them, and some exemplar implementations in the community.

220 citations


Journal ArticleDOI
TL;DR: Epigenetic changes in glucocorticoid signaling, serotonergic signaling, and neurotrophin genes appear to be the most promising therapeutic targets for future research, however, continued research is warranted due to inconsistent findings regarding the directionality of epigenetic modification.

213 citations


Journal ArticleDOI
TL;DR: Pharmacological treatments are often needed to insure weight loss and weight maintenance as adjuncts to diet and physical activity in people with obesity and overweight patients.
Abstract: This is an overview of the mechanisms of obesity and its relation to cardiovascular risks, describing the available treatment options to manage this condition. The pathogenesis of obesity includes the balance between calories consumed and energy expenditure followed by the maintenance of body weight. Diet, physical activity, environmental, behavioral and physiological factors are part of the complex process of weight loss, since there are several hormones and peptides involved in regulation of appetite, eating behavior and energy expenditure. The cardiovascular complications associated to obesity are also driven by processes involving hormones and peptides and which include inflammation, insulin resistance, endothelial dysfunction, coronary calcification, activation of coagulation, renin angiotensin or the sympathetic nervous systems. Pharmacological treatments are often needed to insure weight loss and weight maintenance as adjuncts to diet and physical activity in people with obesity and overweight patients. To accomplish satisfactory goals, patients and physicians seek for weight loss, weight maintenance and improvement of the risk factors associated to this condition, especially cardiovascular risk.

199 citations


Journal ArticleDOI
TL;DR: The ICAP consensus is presented on the clinical relevance of the 29 distinct HEp-2 IIFA patterns: this clinical relevance is primarily defined within the context of the suspected disease and includes recommendations for follow-up testing.
Abstract: The indirect immunofluorescence assay (IIFA) on HEp-2 cells is widely used for detection of antinuclear antibodies (ANA). The dichotomous outcome, negative or positive, is integrated in diagnostic and classification criteria for several systemic autoimmune diseases. However, the HEp-2 IIFA test has much more to offer: besides the titre or fluorescence intensity, it also provides fluorescence pattern(s). The latter include the nucleus and the cytoplasm of interphase cells as well as patterns associated with mitotic cells. The International Consensus on ANA Patterns (ICAP) initiative has previously reached consensus on the nomenclature and definitions of HEp-2 IIFA patterns. In the current paper, the ICAP consensus is presented on the clinical relevance of the 29 distinct HEp-2 IIFA patterns. This clinical relevance is primarily defined within the context of the suspected disease and includes recommendations for follow-up testing. The discussion includes how this information may benefit the clinicians in daily practice and how the knowledge can be used to further improve diagnostic and classification criteria.

199 citations


Journal ArticleDOI
01 Mar 2019-Cornea
TL;DR: A global consensus is reached on the definition, classification, diagnosis, and staging of LSCD, which will facilitate a better understanding of the condition and help with clinical management, research, and clinical trials in this area.
Abstract: Purpose:Despite extensive knowledge gained over the last 3 decades regarding limbal stem cell deficiency (LSCD), the disease is not clearly defined, and there is lack of agreement on the diagnostic criteria, staging, and classification system among treating physicians and research scientists working

Journal ArticleDOI
TL;DR: The most recent evidence that renal inflammation can be ameliorated by interfering with the gut microbiota through the administration of probiotics, prebiotics, and postbiotics is summarized and the recent discovery of new targets for drugs long in use in clinical practice is addressed.
Abstract: Inflammation, a process intimately linked to renal disease, can be defined as a complex network of interactions between renal parenchymal cells and resident immune cells, such as macrophages and dendritic cells, coupled with recruitment of circulating monocytes, lymphocytes, and neutrophils. Once stimulated, these cells activate specialized structures such as Toll-like receptor and Nod-like receptor (NLR). By detecting danger-associated molecules, these receptors can set in motion major innate immunity pathways such as nuclear factor ĸB (NF-ĸB) and NLRP3 inflammasome, causing metabolic reprogramming and phenotype changes of immune and parenchymal cells and triggering the secretion of a number of inflammatory mediators that can cause irreversible tissue damage and functional loss. Growing evidence suggests that this response can be deeply impacted by the crosstalk between the kidneys and other organs, such as the gut. Changes in the composition and/or metabolite production of the gut microbiota can influence inflammation, oxidative stress, and fibrosis, thus offering opportunities to positively manipulate the composition and/or functionality of gut microbiota and, consequentially, ameliorate deleterious consequences of renal diseases. In this review, we summarize the most recent evidence that renal inflammation can be ameliorated by interfering with the gut microbiota through the administration of probiotics, prebiotics, and postbiotics. In addition to these innovative approaches, we address the recent discovery of new targets for drugs long in use in clinical practice. Angiotensin II receptor antagonists, NF-ĸB inhibitors, thiazide diuretics, and antimetabolic drugs can reduce renal macrophage infiltration and slow down the progression of renal disease by mechanisms independent of those usually attributed to these compounds. Allopurinol, an inhibitor of uric acid production, has been shown to decrease renal inflammation by limiting activation of the NLRP3 inflammasome. So far, these protective effects have been shown in experimental studies only. Clinical studies will establish whether these novel strategies can be incorporated into the arsenal of treatments intended to prevent the progression of human disease.

Journal ArticleDOI
TL;DR: The recent findings on the interplay among SIRT1, oxidative stress, and DNA repair machinery and its impact on normal and cancer cells are discussed.
Abstract: Sirtuin-1 (SIRT1) is a class-III histone deacetylase (HDAC), an NAD+-dependent enzyme deeply involved in gene regulation, genome stability maintenance, apoptosis, autophagy, senescence, proliferation, aging, and tumorigenesis. It also has a key role in the epigenetic regulation of tissue homeostasis and many diseases by deacetylating both histone and non-histone targets. Different studies have shown ambiguous implications of SIRT1 as both a tumor suppressor and tumor promoter. However, this contradictory role seems to be determined by the cell type and SIRT1 localization. SIRT1 upregulation has already been demonstrated in some cancer cells, such as acute myeloid leukemia (AML) and primary colon, prostate, melanoma, and non-melanoma skin cancers, while SIRT1 downregulation was described in breast cancer and hepatic cell carcinomas. Even though new functions of SIRT1 have been characterized, the underlying mechanisms that define its precise role on DNA damage and repair and their contribution to cancer development remains underexplored. Here, we discuss the recent findings on the interplay among SIRT1, oxidative stress, and DNA repair machinery and its impact on normal and cancer cells.

Journal ArticleDOI
TL;DR: Canadians would benefit from reducing consumption of ultra-processed foods and beverages and increasing consumption of freshly prepared dishes made from unprocessed or minimally processed foods.
Abstract: To assess the association between consumption of ultra-processed foods and obesity in the Canadian population. Cross-sectional study including 19,363 adults aged 18 years or more from the 2004 Canadian Community Health Survey, cycle 2.2. Ultra-processed food intake was estimated using daily relative energy intake of ultra-processed food (% of total energy intake) from data obtained by 24-h food recalls. Obesity was assessed using body mass index (BMI ≥ 30 kg/m2). Univariate and multivariate linear regressions were performed to describe ultra-processed food consumption according to socio-economic and demographic variables, and multivariate logistic regression was performed to verify the association between ultra-processed food consumption and obesity, adjusting for potential confounders, including socio-demographic factors, physical activity, smoking, immigrant status, residential location, and measured vs self-reported weight and height. Ultra-processed foods make up almost half (45%) of the daily calories consumed by Canadian adults. Consumption of these foods is higher among men, younger adults, those with fewer years of formal education, smokers, those physically inactive, and Canadian-born individuals. Ultra-processed food consumption is positively associated with obesity. After adjusting for confounding factors, individuals in the highest quintile of ultra-processed food consumption were 32% more likely of having obesity compared to individuals in the first quintile (predicted OR = e0.005 × 56 = 1.32; 95% CI = 1.05–1.57). Canadians would benefit from reducing consumption of ultra-processed foods and beverages and increasing consumption of freshly prepared dishes made from unprocessed or minimally processed foods.

Journal ArticleDOI
TL;DR: Despite great advances in the appreciation of vitamin D metabolism, measurements, biological actions on classical and nonclassical tissues, and therapeutics, much more work remains to be done so that the knowledge base can become even more secure.
Abstract: Context Vitamin D is classically recognized as a regulator of calcium and phosphorus metabolism. Recent advances in the measurement of vitamin D metabolites, diagnosis of vitamin D deficiency, and clinical observations have led to an appreciation that along with its role in skeletal metabolism, vitamin D may well have an important role in nonclassical settings. Measurement of the circulating form of vitamin D that best describes total body stores, namely 25-hydroxyvitamin D, can be unreliable despite many sophisticated methodologies that have been proposed and implemented. Likewise, evidence from clinical studies showing a beneficial role of vitamin D in different disease states has been controversial and at times speculative. Moreover, the target concentrations of 25-hydroxyvitamin D to address a number of putative links between vitamin D inadequacy and nonskeletal diseases are further areas of uncertainty. Setting To address these issues, an international conference on "Controversies in Vitamin D" was held in Pisa, Italy, in June 2017. Three main topics were addressed: (i) vitamin D assays and the definition of hypovitaminosis D; (ii) skeletal and extraskeletal effects of vitamin D; (iii) therapeutics of vitamin D. Results This report provides a summary of the deliberations of the expert panels of the conference. Conclusions Despite great advances in our appreciation of vitamin D metabolism, measurements, biological actions on classical and nonclassical tissues, and therapeutics, all of which this report summarizes, much more work remains to be done so that our knowledge base can become even more secure.

Journal ArticleDOI
TL;DR: In this article, the authors present a dedicated complementarity study of gravitational wave and collider measurements of the simplest extension of the Higgs sector: the singlet scalar augmented Standard Model.
Abstract: We present a dedicated complementarity study of gravitational wave and collider measurements of the simplest extension of the Higgs sector: the singlet scalar augmented Standard Model. We study the following issues: (i) the electroweak phase transition patterns admitted by the model, and the proportion of parameter space for each pattern; (ii) the regions of parameter space that give detectable gravitational waves at future space-based detectors; and (iii) the current and future collider measurements of di-Higgs production, as well as searches for a heavy weak diboson resonance, and how these searches interplay with regions of parameter space that exhibit strong gravitational wave signals. We carefully investigate the behavior of the normalized energy released during the phase transition as a function of the model parameters, address subtle issues pertaining to the bubble wall velocity, and provide a description of different fluid velocity profiles. On the collider side, we identify the subset of points that are most promising in terms of di-Higgs and weak diboson production studies while also giving detectable signals at LISA, setting the stage for future benchmark points that can be used by both communities.

Journal ArticleDOI
TL;DR: A major challenge in evaluating the host response in sepsis is to characterize what is protective and what is harmful, and it is discussed that, at least in part, the apparent dysregulated host response may be an effort to adapt to a hostile environment.
Abstract: Sepsis remains a major cause of morbidity and mortality worldwide, with increased burden in low- and middle-resource settings. The role of the inflammatory response in the pathogenesis of the syndrome has supported the modern concept of sepsis. Nevertheless, a definition of sepsis and the criteria for its recognition is a continuous process, which reflects the growing knowledge of its mechanisms and the success and failure of diagnostic and therapeutic interventions. Here we review the evolving concepts of sepsis, from the "systemic inflammatory response syndrome triggered by infection" (Sepsis-1) to "a severe, potentially fatal, organic dysfunction caused by an inadequate or dysregulated host response to infection" (Sepsis-3). We focused in the pathophysiology behind the concept and the criteria for recognition and diagnosis of sepsis. A major challenge in evaluating the host response in sepsis is to characterize what is protective and what is harmful, and we discuss that, at least in part, the apparent dysregulated host response may be an effort to adapt to a hostile environment. The new criteria for recognition and diagnosis of sepsis were derived from robust databases, restricted, however, to developed countries. Since then, the criteria have been supported in different clinical settings and in different economic and epidemiological contexts, but still raise discussion regarding their use for the identification versus the prognostication of the septic patient. Clinicians should not be restricted to definition criteria when evaluating patients with infection and should wisely use the broad array of information obtained by rigorous clinical observation.

Journal ArticleDOI
Dalton Bertolim Précoma1, Gláucia Maria Moraes de Oliveira2, Antonio Felipe Simão, Oscar Pereira Dutra, Otávio Rizzi Coelho3, Maria Cristina de Oliveira Izar4, Rui Manuel dos Santos Póvoa4, Isabela de Carlos Back Giuliano5, Aristóteles Comte de Alencar Filho6, Carlos Alberto Machado7, Carlos Scherr7, Francisco Antonio Helfenstein Fonseca4, Raul Dias dos Santos Filho8, Tales de Carvalho9, Alvaro Avezum, Roberto Esporcatte10, Bruno Ramos Nascimento11, David de Pádua Brasil, Gabriel Porto Soares2, Paolo Blanco Villela2, Roberto Muniz Ferreira2, Wolney de Andrade Martins12, Andrei C. Sposito3, Bruno Halpern8, José Francisco Kerr Saraiva, Luiz Sergio F. Carvalho3, Marcos Antonio Tambascia3, Otavio R. Coelho-Filho3, Adriana Bertolami, Harry Correa Filho, Hermes Toros Xavier, José Rocha Faria-Neto1, Marcelo Chiara Bertolami, Viviane Zorzanelli Rocha Giraldez8, Andréa Araujo Brandão10, Audes D. M. Feitosa, Celso Amodeo4, D Souza13, Eduardo Costa Duarte Barbosa, Marcus Vinícius Bolívar Malachias, Weimar Kunz Sebba Barroso de Souza14, Fernando Augusto Alves da Costa, Ivan Romero Rivera15, Lucia Campos Pellanda16, Maria Alayde Mendonça da Silva15, Aloyzio Cechella Achutti17, André Ribeiro Langowiski, Carla Janice Baister Lantieri, Jaqueline Scholz8, Silvia Maria Cury Ismael, José Carlos Aidar Ayoub18, Luiz César Nazário Scala19, Mario Fritsch Neves10, Paulo César Brandão Veiga Jardim14, Sandra C. Fuchs17, Thiago Veiga Jardim14, Emílio Hideyuki Moriguchi17, Jamil Cherem Schneider, Marcelo Heitor Vieira Assad, S Kaiser10, Ana Maria Lottenberg8, Carlos Daniel Magnoni, Marcio H. Miname8, Roberta Soares Lara, Artur Haddad Herdy, Claudio Gil Soares de Araújo, Mauricio Milani, Miguel Morita Fernandes da Silva20, Ricardo Stein17, Fernando A. Lucchese, Fernando Nobre8, Hermilo Borba Griz, Lucélia Batista Neves Cunha Magalhães21, Mario Henrique Elesbão de Borba21, Mauro Ricardo Nunes Pontes, Ricardo Mourilhe-Rocha10 
TL;DR: The Brazilian Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019 updates the strategies that address classical risk factors and discusses new concepts, such as the need to gather knowledge about emerging risk factors, as well as additional strategies, like the use of vaccines.
Abstract: Introducao A doenca cardiovascular (DCV) e a principal causa de morte no Brasil e no mundo, determinando aumento da morbidade e incapacidade ajustadas pelos anos de vida. Embora as taxas de mortalidade e disability-adjusted life year (DALY) padronizadas por idade estejam diminuindo no Brasil, possivelmente como resultado de politicas de saude bem-sucedidas, o numero total destas esta aumentando principalmente devido ao envelhecimento e adoecimento da populacao. A presenca dos fatores de risco classicos (hipertensao, dislipidemia, obesidade, sedentarismo, tabagismo, diabetes e [...]

Journal ArticleDOI
TL;DR: An updated review on the management of arterial hypertension to prevent the first episode and the recurrence of stroke and a discussion on blood pressure management in hypertensive urgencies and emergencies is presented.
Abstract: Stroke is the second most common cause of mortality worldwide and the third most common cause of disability. Hypertension is the most prevalent risk factor for stroke. Stroke causes and haemodynamic consequences are heterogeneous which makes the management of blood pressure in stroke patients complex requiring an accurate diagnosis and precise definition of therapeutic goals. In this article, the authors provide an updated review on the management of arterial hypertension to prevent the first episode and the recurrence. They also present a discussion on blood pressure management in hypertensive urgencies and emergencies, especially in the acute phase of hypertensive encephalopathy, ischaemic stroke and haemorrhagic stroke.

Journal ArticleDOI
16 Jul 2019-JAMA
TL;DR: A flexible family visitation policy in the ICU, vs standard restricted visiting hours, did not significantly reduce the incidence of delirium, and staff burnout and burnout for ICU staff was not significantly different.
Abstract: Importance The effects of intensive care unit (ICU) visiting hours remain uncertain. Objective To determine whether a flexible family visitation policy in the ICU reduces the incidence of delirium. Design, Setting and Participants Cluster-crossover randomized clinical trial involving patients, family members, and clinicians from 36 adult ICUs with restricted visiting hours ( Interventions Flexible visitation (up to 12 hours per day) supported by family education (n = 837 patients, 652 family members, and 435 clinicians) or usual restricted visitation (median, 1.5 hours per day; n = 848 patients, 643 family members, and 391 clinicians). Nineteen ICUs started with flexible visitation, and 17 started with restricted visitation. Main Outcomes and Measures Primary outcome was incidence of delirium during ICU stay, assessed using the CAM-ICU. Secondary outcomes included ICU-acquired infections for patients; symptoms of anxiety and depression assessed using the HADS (range, 0 [best] to 21 [worst]) for family members; and burnout for ICU staff (Maslach Burnout Inventory). Results Among 1685 patients, 1295 family members, and 826 clinicians enrolled, 1685 patients (100%) (mean age, 58.5 years; 47.2% women), 1060 family members (81.8%) (mean age, 45.2 years; 70.3% women), and 737 clinicians (89.2%) (mean age, 35.5 years; 72.9% women) completed the trial. The mean daily duration of visits was significantly higher with flexible visitation (4.8 vs 1.4 hours; adjusted difference, 3.4 hours [95% CI, 2.8 to 3.9];P Conclusions and Relevance Among patients in the ICU, a flexible family visitation policy, vs standard restricted visiting hours, did not significantly reduce the incidence of delirium. Trial Registration ClinicalTrials.gov Identifier:NCT02932358

Journal ArticleDOI
TL;DR: Infliximab did not significantly reduce depressive symptoms compared with placebo in adults with bipolar depression, and a significant treatment-time and childhood maltreatment interaction was observed in which infliximab-treated individuals with childhood history of physical abuse exhibited greater reductions in MADRS total score.
Abstract: Importance To our knowledge, no study has previously evaluated whether individuals with bipolar depression enriched a priori on the basis of biochemical and/or phenotypic immuno-inflammatory activation would differentially respond to an anti-inflammatory agent for the treatment of depressive symptoms. Objective To assess the antidepressant efficacy of adjunctive infliximab, a monoclonal antibody targeting tumor necrosis factor, in adults with bipolar I and bipolar II depression and inflammatory conditions. Design, Setting, and Participants This 12-week, randomized, double-blind, placebo-controlled, parallel-group trial of 60 participants was conducted at 2 outpatient tertiary care sites in Canada and the United States. Eligible adults (aged 18-65 years) met DSM-5 –defined criteria for bipolar I or bipolar II depression and exhibited pretreatment biochemical and/or phenotypic evidence of inflammatory activation. Participants were enrolled between October 1, 2015, and April 30, 2018. Data analysis was performed from May 1 through July 31, 2018, using modified intent-to-treat analysis. Interventions Patients were randomized to receive 3 intravenous infusions of infliximab therapy or placebo at baseline and at weeks 2 and 6 of the 12-week study. Main Outcomes and Measures The primary efficacy outcome was baseline-to–end point (ie, week-12) change in Montgomery-Asberg Depression Rating Scale (MADRS) total score. History of childhood maltreatment, as assessed by the Childhood Trauma Questionnaire, was used for exploratory analyses as 1 of several secondary outcomes. Results A total of 60 participants were randomized to infliximab (n = 29 [48%]; mean [SD] age, 45.0 [11.7] years; 20 of 28 female [71%]) or to placebo (n = 31 [52%]; mean [SD] age, 46.8 [10.2] years; 26 of 30 female [87%]) across study sites. Overall baseline-to–end point change in MADRS total score was observed across treatment × time interaction (χ 2 = 10.33; P = .04); reduction in symptom severity was not significant at week 12 (relative risk, 1.09; 95% CI, 0.80-1.50; df = 1; P = .60). As part of a secondary analysis, a significant treatment × time × childhood maltreatment interaction was observed in which infliximab-treated individuals with childhood history of physical abuse exhibited greater reductions in MADRS total score (χ 2 = 12.20; P = .02) and higher response rates (≥50% reduction in MADRS total score) (χ 2 = 4.05; P = .04). Conclusions and Relevance Infliximab did not significantly reduce depressive symptoms compared with placebo in adults with bipolar depression. Results from secondary analyses identified a subpopulation (ie, those reporting physical and/or sexual abuse) that exhibited a significant reduction in depressive symptoms with infliximab treatment compared with placebo. Trial Registration ClinicalTrials.gov identifier:NCT02363738

Journal ArticleDOI
TL;DR: Alginate nanoparticles composed of alginate have emerged as one of the most extensively characterized biomaterials used for drug delivery and targeting a set of administration routes and their toxicological profile will determine the therapeutic outcome of the drug delivery system are revised.
Abstract: Nanotechnology refers to the control, manipulation, study and manufacture of structures and devices at the nanometer size range. The small size, customized surface, improved solubility and multi-functionality of nanoparticles will continue to create new biomedical applications, as nanoparticles allow to dominate stability, solubility and bioavailability, as well controlled release of drugs. The type of a nanoparticle, and its related chemical, physical and morphological properties influence its interaction with living cells, as well as determine the route of clearance and possible toxic effects. This field requires cross-disciplinary research and gives opportunities to design and develop multifunctional devices, which allow the diagnosis and treatment of devastating diseases. Over the past few decades, biodegradable polymers have been studied for the fabrication of drug delivery systems. There was extensive development of biodegradable polymeric nanoparticles for drug delivery and tissue engineering, in view of their applications in controlling the release of drugs, stabilizing labile molecules from degradation and site-specific drug targeting. The primary aim is to reduce dosing frequency and prolong the therapeutic outcomes. For this purpose, inert excipients should be selected, being biopolymers, e.g. sodium alginate, commonly used in controlled drug delivery. Nanoparticles composed of alginate (known as anionic polysaccharide widely distributed in the cell walls of brown algae which, when in contact with water, forms a viscous gum) have emerged as one of the most extensively characterized biomaterials used for drug delivery and targeting a set of administration routes. Their advantages include not only the versatile physicochemical properties, which allow chemical modifications for site-specific targeting but also their biocompatibility and biodegradation profiles, as well as mucoadhesiveness. Furthermore, mechanical strength, gelation, and cell affinity can be modulated by combining alginate nanoparticles with other polymers, surface tailoring using specific targeting moieties and by chemical or physical cross-linking. However, for every physicochemical modification in the macromolecule/ nanoparticles, a new toxicological profile may be obtained. In this paper, the different aspects related to the use of alginate nanoparticles for drug delivery and targeting have been revised, as well as how their toxicological profile will determine the therapeutic outcome of the drug delivery system.

Journal ArticleDOI
Jasmeet Soar1, Ian Maconochie2, Myra H. Wyckoff3, Theresa M. Olasveengen4, Eunice M. Singletary5, Robert Greif6, Richard Aickin7, Farhan Bhanji8, Michael W. Donnino9, Mary E. Mancini10, Jonathan Wyllie11, David Zideman, Lars W. Andersen12, Dianne L. Atkins13, Khalid Aziz14, Jason C Bendall15, Katherine Berg9, David C. Berry16, Blair L. Bigham17, Robert Bingham18, Thomaz Bittencourt Couto19, Bernd W. Böttiger20, Vere Borra, Janet Bray21, Jan Breckwoldt22, Steven C. Brooks23, Jason E. Buick24, Clifton W. Callaway25, Jestin N. Carlson, Pascal Cassan, Maaret Castrén, Wei-Tien Chang26, Nathan P. Charlton5, Adam Cheng27, Sung Phil Chung28, Julie Considine29, Keith Couper30, Katie N. Dainty31, Jennifer A Dawson, Maria Fernanda Branco de Almeida32, Allan R. de Caen14, Charles D. Deakin33, Ian R. Drennan24, Jonathan Duff7, Jonathan L. Epstein34, Raffo Escalante35, Raúl J. Gazmuri36, Elaine Gilfoyle27, Asger Granfeldt12, Anne-Marie Guerguerian24, Ruth Guinsburg32, Tetsuo Hatanaka, Mathias J. Holmberg12, Natalie Hood37, Shigeharu Hosono38, Ming-Ju Hsieh26, Tetsuya Isayama, Taku Iwami39, Jan L Jensen40, Vishal S. Kapadia3, Han Suk Kim41, Monica E. Kleinman7, Peter J. Kudenchuk42, Eddy Lang27, Eric J. Lavonas43, Helen G. Liley, Swee Han Lim44, Andrew Lockey, Bo Løfgren12, Matthew Huei-Ming Ma26, David Markenson, Peter A. Meaney45, D. Meyran, Lindsay Mildenhall, Koenraad G. Monsieurs46, William H. Montgomery, Peter T. Morley47, Laurie J. Morrison24, Vinay M. Nadkarni48, Kevin Nation, Robert W. Neumar49, Kee Chong Ng7, Tonia Nicholson50, Nikolaos I. Nikolaou, Chika Nishiyama39, Gabrielle Nuthall7, Shinichiro Ohshimo, Deems Okamoto, Brian J. O'Neil51, Gene Yong-Kwang Ong7, Edison F. Paiva19, Michael Parr52, Jeffrey L. Pellegrino, Gavin D. Perkins53, Jeffrey M. Perlman54, Yacov Rabi27, Amelia G. Reis, Joshua C. Reynolds55, Giuseppe Ristagno56, Charles Christoph Roehr57, Tetsuya Sakamoto58, Claudio Sandroni59, Stephen M. Schexnayder60, Barnaby R. Scholefield61, Naoki Shimizu, Markus B. Skrifvars62, Michael Smyth30, David Stanton, Janel Swain, Edgardo Szyld63, Janice A. Tijssen64, Andrew H. Travers, Daniele Trevisanuto65, Christian Vaillancourt66, Patrick Van de Voorde67, Sithembiso Velaphi, Tzong Luen Wang, Gary M. Weiner49, Michelle Welsford17, Jeff A. Woodin, Joyce Yeung30, Jerry P. Nolan30, Mary Fran Hazinski68 
North Bristol NHS Trust1, Imperial College Healthcare2, University of Texas Southwestern Medical Center3, University of Oslo4, University of Virginia5, University Hospital of Bern6, Boston Children's Hospital7, McGill University8, Beth Israel Deaconess Medical Center9, University of Texas at Arlington10, James Cook University Hospital11, Aarhus University12, University of Iowa13, University of Alberta14, University of Western Australia15, Saginaw Valley State University16, McMaster University17, Great Ormond Street Hospital for Children NHS Foundation Trust18, University of São Paulo19, University of Cologne20, Monash University21, University of Zurich22, Queen's University23, University of Toronto24, University of Pittsburgh25, National Taiwan University26, University of Calgary27, Yonsei University28, Deakin University29, University of Warwick30, North York General Hospital31, Federal University of São Paulo32, University of Southampton33, American Red Cross34, Universidad Peruana de Ciencias Aplicadas35, Rosalind Franklin University of Medicine and Science36, Florey Institute of Neuroscience and Mental Health37, Jichi Medical University38, Kyoto University39, Dalhousie University40, Seoul National University Hospital41, University of Washington42, Denver Health Medical Center43, Singapore General Hospital44, Stanford University45, University of Antwerp46, University of Melbourne47, Children's Hospital of Philadelphia48, University of Michigan49, Waikato Hospital50, Wayne State University51, Liverpool Hospital52, Heart of England NHS Foundation Trust53, Cornell University54, Michigan State University55, University of Milan56, University of Oxford57, Teikyo University58, Catholic University of the Sacred Heart59, University of Arkansas60, University of Birmingham61, University of Helsinki62, University of Oklahoma63, University of Western Ontario64, University of Padua65, Ottawa Hospital Research Institute66, Ghent University67, Vanderbilt University68
TL;DR: This summary addresses the role of cardiac arrest centers and dispatcher-assisted cardiopulmonary resuscitation, the role for presyncope by first aid providers, advanced airway interventions in adults and children, targeted temperature management in children after cardiac arrest, and initial oxygen concentration during resuscitation of newborns.
Abstract: The International Liaison Committee on Resuscitation has initiated a continuous review of new, peer-reviewed, published cardiopulmonary resuscitation science. This is the third annual summary of the International Liaison Committee on Resuscitation International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. It addresses the most recent published resuscitation evidence reviewed by International Liaison Committee on Resuscitation Task Force science experts. This summary addresses the role of cardiac arrest centers and dispatcher-assisted cardiopulmonary resuscitation, the role of extracorporeal cardiopulmonary resuscitation in adults and children, vasopressors in adults, advanced airway interventions in adults and children, targeted temperature management in children after cardiac arrest, initial oxygen concentration during resuscitation of newborns, and interventions for presyncope by first aid providers. Members from 6 International Liaison Committee on Resuscitation task forces have assessed, discussed, and debated the certainty of the evidence on the basis of the Grading of Recommendations, Assessment, Development, and Evaluation criteria, and their statements include consensus treatment recommendations. Insights into the deliberations of the task forces are provided in the Justification and Evidence to Decision Framework Highlights sections. The task forces also listed priority knowledge gaps for further research.

Journal ArticleDOI
TL;DR: Important temporal decreases in susceptibility rates among Acb complex isolates were observed for all antimicrobial agents in all regions, and important reductions of susceptibility rates to all antimicrobials obtained from all geographic regions were observed.
Abstract: Background Acinetobacter calcoaceticus-A. baumannii (Acb) complex and Stenotrophomonas maltophilia represent frequent causes of hospital-acquired infections. We evaluated the frequency and resistance rates of Acb complex and S. maltophilia isolates from medical centers enrolled in the SENTRY Program. Methods A total of 13 752 Acb complex and 6467 S. maltophilia isolates were forwarded to a monitoring laboratory by 259 participating sites from the Asia-Pacific region, Latin America, Europe, and North America between 1997 and 2016. Confirmation of species identification and antimicrobial susceptibility testing were performed using conventional methods and/or matrix-assisted laser desorption ionization-time of flight mass spectrometry and the broth microdilution method, respectively. Antimicrobial susceptibility results were interpreted by CLSI and EUCAST 2018 criteria. Results Acb complex and S. maltophilia were most frequently isolated from patients hospitalized with pneumonia (42.9% and 55.8%, respectively) and bloodstream infections (37.3% and 33.8%, respectively). Colistin and minocycline were the most active agents against Acb complex (colistin MIC50/90, ≤0.5/2 mg/L; 95.9% susceptible) and S. maltophilia (minocycline MIC50/90, ≤1/2 mg/L; 99.5% susceptible) isolates, respectively. Important temporal decreases in susceptibility rates among Acb complex isolates were observed for all antimicrobial agents in all regions. Rates of extensively drug-resistant Acb complex rates were highest in Europe (66.4%), followed by Latin America (61.5%), Asia-Pacific (56.9%), and North America (38.8%). Among S. maltophilia isolates, overall trimethoprim-sulfamethoxazole (TMP-SMX) susceptibility rates decreased from 97.2% in 2001-2004 to 95.7% in 2013-2016, but varied according to the geographic region. Conclusions We observed important reductions of susceptibility rates to all antimicrobial agents among Acb complex isolates obtained from all geographic regions. In contrast, resistance rates to TMP-SMX among S. maltophilia isolates remained low and relatively stable during the study period.

Journal ArticleDOI
Jasmeet Soar1, Ian Maconochie2, Myra H. Wyckoff3, Theresa M. Olasveengen4, Eunice M. Singletary5, Robert Greif6, Robert Greif7, Richard Aickin, Farhan Bhanji8, Michael W. Donnino9, Mary E. Mancini10, Jonathan Wyllie11, David Zideman, Lars W. Andersen12, Dianne L. Atkins13, Khalid Aziz14, Jason C Bendall15, Katherine Berg9, David C. Berry16, Blair L. Bigham17, Robert Bingham18, Thomaz Bittencourt Couto19, Bernd W. Böttiger20, Vere Borra, Janet Bray21, Jan Breckwoldt22, Steven C. Brooks23, Jason E. Buick24, Clifton W. Callaway25, Jestin N. Carlson26, Pascal Cassan27, Maaret Castrén28, Wei-Tien Chang29, Nathan P. Charlton5, Adam Cheng30, Sung Phil Chung31, Julie Considine32, Keith Couper33, Katie N. Dainty34, Jennifer A Dawson35, Maria Fernanda Branco de Almeida36, Allan R. de Caen14, Charles D. Deakin37, Ian R. Drennan38, Jonathan P. Duff14, Jonathan P. Duff39, Jonathan L. Epstein40, Raffo Escalante41, Raúl J. Gazmuri42, Elaine Gilfoyle30, Asger Granfeldt43, Anne Marie Guerguerian44, Ruth Guinsburg36, Tetsuo Hatanaka, Mathias J. Holmberg12, Natalie Hood45, Shigeharu Hosono46, Ming-Ju Hsieh29, Tetsuya Isayama, Taku Iwami47, Jan L Jensen48, Vishal S. Kapadia3, Han Suk Kim, Monica E. Kleinman39, Peter J. Kudenchuk49, Eddy Lang50, Eric J. Lavonas51, Helen G. Liley52, Swee Han Lim53, Andrew Lockey54, Bo Løfgren43, Matthew Huei-Ming Ma29, David Markenson, Peter A. Meaney55, D. Meyran, Lindsay Mildenhall56, Koenraad G. Monsieurs, William H. Montgomery, Peter T. Morley57, Peter T. Morley58, Laurie J. Morrison, Vinay M. Nadkarni59, Kevin Nation, Robert W. Neumar60, Kee Chong Ng39, Tonia Nicholson61, Nikolaos I. Nikolaou, Chika Nishiyama47, Gabrielle Nuthall, Shinichiro Ohshimo, Deems Okamoto, Brian J. O'Neil62, Gene Yong-Kwang Ong39, Edison F. Paiva19, Michael Parr63, Jeffrey L. Pellegrino, Gavin D. Perkins33, Gavin D. Perkins64, Jeffrey M. Perlman65, Yacov Rabi50, Amelia G. Reis41, Joshua C. Reynolds66, Giuseppe Ristagno67, Charles Christoph Roehr68, Tetsuya Sakamoto69, Claudio Sandroni70, Claudio Sandroni71, Stephen M. Schexnayder72, Stephen M. Schexnayder73, Barnaby R. Scholefield74, Naoki Shimizu75, Markus B. Skrifvars76, Markus B. Skrifvars28, Michael Smyth33, David Stanton, Janel Swain, Edgardo Szyld, Janice A. Tijssen77, Andrew H. Travers, Daniele Trevisanuto78, Christian Vaillancourt79, Christian Vaillancourt80, Patrick Van de Voorde81, Sithembiso Velaphi, Tzong Luen Wang82, Gary M. Weiner60, Michelle Welsford83, Jeff A. Woodin, Joyce Yeung33, Jerry P. Nolan33, Mary Fran Hazinski84 
North Bristol NHS Trust1, Imperial College Healthcare2, University of Texas Southwestern Medical Center3, Oslo University Hospital4, University of Virginia5, University of Bern6, University Hospital of Bern7, McGill University8, Beth Israel Deaconess Medical Center9, University of Texas at Arlington10, James Cook University Hospital11, Aarhus University12, University of Iowa13, University of Alberta14, University of Newcastle15, Saginaw Valley State University16, McMaster University17, Great Ormond Street Hospital for Children NHS Foundation Trust18, University of São Paulo19, University of Cologne20, Alfred Hospital21, University of Zurich22, Queen's University23, University of Toronto24, University of Pittsburgh25, Allegheny Health Network26, International Federation of Red Cross and Red Crescent Societies27, Helsinki University Central Hospital28, National Taiwan University29, Alberta Children's Hospital30, Yonsei University31, Deakin University32, University of Warwick33, Northern General Hospital34, Royal Women's Hospital35, Federal University of São Paulo36, University of Southampton37, St. Michael's GAA, Sligo38, Boston Children's Hospital39, American Red Cross40, National Heart Foundation of Australia41, Rosalind Franklin University of Medicine and Science42, Aarhus University Hospital43, Hospital for Sick Children44, Monash Medical Centre45, Jichi Medical University46, Kyoto University47, Dalhousie University48, University of Washington Medical Center49, University of Calgary50, Denver Health Medical Center51, Mater Health Services52, Singapore General Hospital53, European Resuscitation Council54, Stanford University55, Middlemore Hospital56, University of Melbourne57, Royal Melbourne Hospital58, Children's Hospital of Philadelphia59, University of Michigan60, Waikato Hospital61, Wayne State University62, Liverpool Hospital63, Heart of England NHS Foundation Trust64, Cornell University65, Michigan State University66, University of Milan67, University of Oxford68, Teikyo University69, Catholic University of the Sacred Heart70, Agostino Gemelli University Polyclinic71, Arkansas Children's Hospital72, University of Arkansas73, University of Birmingham74, St. Marianna University School of Medicine75, University of Helsinki76, London Health Sciences Centre77, University of Padua78, Ottawa Hospital79, University of Ottawa80, Ghent University81, Memorial Hospital of South Bend82, Hamilton Health Sciences83, Vanderbilt University84
TL;DR: This summary addresses the role of cardiac arrest centers and dispatcher-assisted cardiopulmonary resuscitation, the role for presyncope by first aid providers, advanced airway interventions in adults and children, targeted temperature management in children after cardiac arrest, and initial oxygen concentration during resuscitation of newborns.

Journal ArticleDOI
TL;DR: The meeting culminated with the adoption of the special Gramado Declaration, signed by all Ministerial officials who attended the meeting and an opportunity now exists to translate this Declaration into an action plan to reduce the burden of stroke.
Abstract: Summary The large and increasing burden of stroke in Latin American countries, and the need to meet the UN and WHO requirements for reducing the burden from non-communicable disorders (including stroke), brought together stroke experts and representatives of the Ministries of Health of 13 Latin American countries for the 1st Latin American Stroke Ministerial meeting in Gramado, Brazil, to discuss the problem and identify ways of cooperating to reduce the burden of stroke in the region. Discussions were focused on the regional and country-specific activities associated with stroke prevention and treatment, including public stroke awareness, prevention strategies, delivery and organisation of care, clinical practice gaps, and unmet needs. The meeting culminated with the adoption of the special Gramado Declaration, signed by all Ministerial officials who attended the meeting. With agreed priorities for stroke prevention, treatment, and research, an opportunity now exists to translate this Declaration into an action plan to reduce the burden of stroke.

Journal ArticleDOI
TL;DR: This study provides Class II evidence that the RCVS2 score accurately distinguishes patients with RCVS from those with other intracranial arteriopathies upon admission, using widely available clinical and imaging features.
Abstract: Objective To develop a method to distinguish reversible cerebral vasoconstriction syndrome (RCVS) from other large/medium-vessel intracranial arteriopathies. Methods We identified consecutive patients from our institutional databases admitted in 2013–2017 with newly diagnosed RCVS (n = 30) or non-RCVS arteriopathy (n = 80). Admission clinical and imaging features were compared. Multivariate logistic regression modeling was used to develop a discriminatory score. Score validity was tested in a separate cohort of patients with RCVS and its closest mimic, primary angiitis of the CNS (PACNS). In addition, key variables were used to develop a bedside approach to distinguish RCVS from non-RCVS arteriopathies. Results The RCVS group had significantly more women, vasoconstrictive triggers, thunderclap headaches, normal brain imaging results, and better outcomes. Beta coefficients from the multivariate regression model yielding the best c-statistic (0.989) were used to develop the RCVS2 score (range −2 to +10; recurrent/single thunderclap headache; carotid artery involvement; vasoconstrictive trigger; sex; subarachnoid hemorrhage). Score ≥5 had 99% specificity and 90% sensitivity for diagnosing RCVS, and score ≤2 had 100% specificity and 85% sensitivity for excluding RCVS. Scores 3–4 had 86% specificity and 10% sensitivity for diagnosing RCVS. The score showed similar performance to distinguish RCVS from PACNS in the validation cohort. A clinical approach based on recurrent thunderclap headaches, trigger and normal brain scans, or convexity subarachnoid hemorrhage correctly diagnosed 25 of 37 patients with RCVS2 scores 3–4 across the derivation and validation cohorts. Conclusion RCVS can be accurately distinguished from other intracranial arteriopathies upon admission, using widely available clinical and imaging features. Classification of evidence This study provides Class II evidence that the RCVS2 score accurately distinguishes patients with RCVS from those with other intracranial arteriopathies.

Journal ArticleDOI
TL;DR: The working group’s main goal was to provide clinicians with clear and practical recommendations to optimize microbiological diagnosis and treatment of IC.
Abstract: The term invasive candidiasis (IC) refers to both bloodstream and deep-seated invasive infections, such as peritonitis, caused by Candida species. Several guidelines on the management of candidemia and invasive infection due to Candida species have recently been published, but none of them focuses specifically on critically ill patients admitted to intensive care units (ICUs). In the absence of available scientific evidence, the resulting recommendations are based solely on epidemiological and clinical evidence in conjunction with expert opinion. The task force used the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach to evaluate the recommendations and assign levels of evidence. The recommendations and their strength were decided by consensus and, if necessary, by vote (modified Delphi process). Descriptive statistics were used to analyze the results of the Delphi process. Statements obtaining > 80% agreement were considered to have achieved consensus. The heterogeneity of this patient population necessitated the creation of a mixed working group comprising experts in clinical microbiology, infectious diseases and intensive care medicine, all chosen on the basis of their expertise in the management of IC and/or research methodology. The working group’s main goal was to provide clinicians with clear and practical recommendations to optimize microbiological diagnosis and treatment of IC. The Systemic Inflammation and Sepsis and Infection sections of the European Society of Intensive Care Medicine (ESICM) and the Critically Ill Patients Study Group of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) therefore decided to develop a set of recommendations for application in non-immunocompromised critically ill patients.

Journal ArticleDOI
TL;DR: The health research involving animals and the current Brazilian framework for regulating laboratory animal science are described and it is hoped to help to improve the awareness of the scientific community of these ethical and legal rules.
Abstract: Animal models have been used in experimental research to increase human knowledge and contribute to finding solutions to biological and biomedical questions. However, increased concern for the welfare of the animals used, and a growing awareness of the concept of animal rights, has brought a greater focus on the related ethical issues. In this review, we intend to give examples on how animals are used in the health research related to some major health problems in Brazil, as well as to stimulate discussion about the application of ethics in the use of animals in research and education, highlighting the role of National Council for the Control of Animal Experimentation (Conselho Nacional de Controle de Experimentacao Animal - CONCEA) in these areas. In 2008, Brazil emerged into a new era of animal research regulation, with the promulgation of Law 11794, previously known as the Arouca Law, resulting in an increased focus, and rapid learning experience, on questions related to all aspects of animal experimentation. The law reinforces the idea that animal experiments must be based on ethical considerations and integrity-based assumptions, and provides a regulatory framework to achieve this. This review describes the health research involving animals and the current Brazilian framework for regulating laboratory animal science, and hopes to help to improve the awareness of the scientific community of these ethical and legal rules.

Journal ArticleDOI
TL;DR: This review summarizes recent findings regarding antifungal therapy and development of resistance related to the fungal cell wall of the most relevant human pathogenic species.
Abstract: The cell wall is an essential component in fungal homeostasis. The lack of a covering wall in human cells makes this component an attractive target for antifungal development. The host environment and antifungal stress can lead to cell wall modifications related to drug resistance. Antifungals targeting the cell wall including the new β-D-glucan synthase inhibitor ibrexafungerp and glycosyl-phosphatidyl Inositol (GPI) anchor pathway inhibitor fosmanogepix are promising weapons against antifungal resistance. The fosmanogepix shows strong in vitro activity against the multidrug-resistant species Candida auris, Fusarium solani, and Lomentospora prolificans. The alternative carbon sources in the infection site change the cell wall β-D-glucan and chitin composition, leading to echinocandin and amphotericin resistance. Candida populations that survive echinocandin exposure develop tolerance and show high chitin content in the cell wall, while fungal species such as Aspergillus flavus with a higher β-D-glucan content may show amphotericin resistance. Therefore understanding fungal cell dynamics has become important not only for host-fungal interactions, but also treatment of fungal infections. This review summarizes recent findings regarding antifungal therapy and development of resistance related to the fungal cell wall of the most relevant human pathogenic species.